Cardiomyopathy
Also known as: Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy, Hypertrophic cardiomyopathy, Myocardiopathy, Restrictive cardiomyopathy
Methodology & AI Transparency ⓘ
Cardiomyopathy Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Cardiomyopathy is the name for diseases of the heart muscle.
- 2 Real-world patient consensus: Mapped to Heart & Cardiovascular Disease under ICD-10-CM I42.9 for Cardiomyopathy clinical workups.
- 3 Typical cash cost range: Differential triage of Cardiomyopathy (I42.9) utilizes ambulatory rhythm monitoring [Cardiomyopathy I42.9].
- 4 Top reported side effects / signs: Longitudinal Cardiomyopathy monitoring tracks Apolipoprotein B (ApoB) [Cardiomyopathy I42.9] toward < 70 mg/dL (I42.9).
Ask our AI Specialists anything about Cardiomyopathy
What Is Cardiomyopathy?
Cardiomyopathy is the name for diseases of the heart muscle. These diseases enlarge your heart muscle or make it thicker and more rigid than normal. In rare cases, scar tissue replaces the muscle tissue. Some people live long, healthy lives with cardiomyopathy. Some people don't even realize they have it. In others, however, it can make the heart less able to pump blood through the body. This can cause serious complications, including: Heart failure Abnormal heart rhythms Heart valve problems Sudden cardiac arrest (SCA) Heart attacks , high blood pressure , infections, and other diseases can all cause cardiomyopathy. Some types of cardiomyopathy run in families.
Pathophysiology, Underlying Causes & Clinical Presentation
In Cardiomyopathy (I42.9), physiological disruption stems from subendocardial perfusion deficits [Cardiomyopathy I42.9], Cross-referenced with NIH MeSH (Cardiomyopathies), informing Heart & Cardiovascular Disease protocols that track Left Ventricular Ejection in Cardiomyopathy (I42.9: Fraction (LVEF)) (55% – 70% (I42.9)).
Common Symptoms & Clinical Signs
- • Abnormal heart rhythms
- • Heart valve problems
- • Presentation of Cardiomyopathy (I42.9): unexplained lower-extremity ankle in Cardiomyopathy (I42.9: edema or rapid)
- • Secondary Cardiomyopathy clinical sign: reduced exercise tolerance in Cardiomyopathy (I42.9: and premature cardiovascular)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Cardiomyopathy Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | I42.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Heart & Cardiovascular Disease | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Apolipoprotein B (ApoB) [Cardiomyopathy I42.9] | < 70 mg/dL (I42.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Left Ventricular Ejection in Cardiomyopathy (I42.9: Fraction (LVEF)) | 55% – 70% (I42.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: NT-proBNP [Cardiomyopathy I42.9] | < 100 pg/mL (I42.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Cardiomyopathy
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Dexrazoxane for Injection Dexrazoxane for Injection Generic • RxCUI 1736590 | Cytoprotective Agent | 81% | $0.8300 | $ 42.12 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Cardiomyopathy)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Causes of heart and blood vessel Hospitalization and Death in Patients With: What a 264-Participant Study Found These data provide further insight into CV disease progression in patients with ATTR-CM, with HF the most common adjudicated cause of CV-related hospitalization or death in ATTR-ACT. The American journal of cardiology • 2021-06-01 • Phase III Randomized Trial | N = 264 | 93/100 | PMID 33667442 ↗ |
| New Insights on Mavacamten - a new disease-specific option for pharmacological treatment of: What a 251-Participant Study Found The safety profile of mavacamten was similar to that of placebo. Kardiologia polska • 2021-01-15 • Phase III Randomized Trial | N = 251 | 93/100 | PMID 34268723 ↗ |
| New Insights on Acoramidis on clinical stability in transthyretin amyloid cardiomyopathy:: What a 611-Participant Study Found Acoramidis led to CMI from baseline in NT-proBNP concentration or 6MWD in a considerable proportion of participants with ATTR-CM. European journal of heart failure • 2026-10-28 • Phase III Randomized Trial | N = 611 | 93/100 | PMID 41771146 ↗ |
| Can This Approach Help? Inside the Latest Research on Baseline characteristics of patients with transthyretin amyloid cardiomyopathy in The baseline characteristics of CARDIO-TTRansform were consistent with previous ATTR-CM trials; however, CARDIO-TTRansform evaluated patients with a wide range of disease severity and receiving the contemporary standard of... European journal of heart failure • 2026-10-28 • Phase III Randomized Trial | N = 130 | 88/100 | PMID 42217207 ↗ |
| Can This Approach Help? Inside the Latest Research on Long-term efficacy of tafamidis in patients with transthyretin amyloid Tafamidis treatment reduced the risk of mortality and hospitalization in patients with NAC stages I/II ATTR-CM, with favourable trends at stage III. European journal of heart failure • 2025-12-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40488446 ↗ |
Cardiomyopathy Patient Community & “People Like Me” Threads
Filter Cardiomyopathy community threads and patient logs by age, biological sex, dosage, and treatment duration.